Exact Sciences Launches Cancerguard, a Blood Test for Early Cancer Detection.

Exact Sciences has launched Cancerguard, a multi-cancer early detection blood test that can detect over 50 cancer types, including hard-to-screen cancers like pancreatic, ovarian, and liver cancers. The test has a 64% overall sensitivity and 97.4% specificity. It is recommended annually for adults aged 50-84 with no recent cancer history and costs $689. Exact Sciences has partnered with Quest Diagnostics to make blood collection available at 7,000 locations nationwide.

Exact Sciences Corp. (Nasdaq: EXAS) has announced the launch of Cancerguard™, a pioneering multi-cancer early detection (MCED) blood test that promises to revolutionize cancer screening. The test, available as a laboratory-developed test (LDT) in the United States, is designed to detect a wide range of cancers, including those that often go undetected until later stages when treatment options are limited.

Cancerguard™ analyzes multiple biomarker classes, making it the first commercially available MCED test to do so. This capability significantly enhances early cancer detection, particularly for hard-to-screen cancers such as pancreatic, ovarian, and liver cancers. The test has demonstrated a 64% overall sensitivity and a high 97.4% specificity, indicating its ability to accurately identify cancer signals while minimizing false positives [1].

The test is priced at $689 and is recommended annually for adults aged 50-84 with no recent cancer history. To ensure broad patient access, Exact Sciences has partnered with Quest Diagnostics, which will facilitate blood collection at approximately 7,000 patient access sites nationwide, including through its patient service centers, in-office phlebotomists, and mobile phlebotomy services for at-home collections [2].

Kevin Conroy, chairman and CEO of Exact Sciences, underscored the significance of Cancerguard™, stating, "Cancerguard builds on the legacy of Cologuard, which has delivered more than 20 million test results and transformed colorectal cancer screening. With strong science and developed to screen for many of the deadliest cancers, the Cancerguard test represents the next bold step in our mission to detect cancer earlier" [3].

The test is the culmination of nearly a decade of development and is backed by rigorous scientific research, including data from robust test-development studies such as DETECT-A and ASCEND 2, involving more than 20,000 participants. To further validate its clinical utility, Exact Sciences is enrolling up to 25,000 participants in the Falcon registry, a real-world evidence study conducted under a U.S. FDA-reviewed Investigational Device Exemption (IDE) [4].

The comprehensive body of evidence supporting Cancerguard™ is designed to inform future regulatory submissions, support payer discussions on coverage and reimbursement, and guide efforts to include the test in clinical guidelines. This approach underscores Exact Sciences' commitment to improving cancer detection and outcomes.

The launch of Cancerguard™ marks a significant milestone in the company's mission to detect cancer earlier and improve patient outcomes. By addressing the unmet need for early detection of cancers without recommended screening, Cancerguard™ has the potential to meaningfully reduce stage IV cancer diagnoses and lower overall cancer-related mortality [5].

Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics, aiming to transform cancer care through innovative solutions. For more information, visit ExactSciences.com.

References:
[1] Exact Sciences Corp. (2025). Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test.
[2] Exact Sciences Corp. (2025). Cancerguard™ Test Overview.
[3] Exact Sciences Corp. (2025). Cancerguard™ Press Release.
[4] Exact Sciences Corp. (2025). Falcon Registry Study.
[5] Jagpreet Chhatwal, Jade Xiao, Andrew ElHabr, et al. (2025). The Potential of Multi-Cancer Early Detection Screening in Reducing Cancer Incidence and Mortality in High-Risk Groups: A Modeling Study. JCO 43, 10542-10542.